Nicozid (Isoniazid)

Isoniazid, the active ingredient in Nicozid, is an antitubercular agent presented as a sterile preparation for intramuscular and cutaneous use. It is employed in the treatment and prevention of tuberculosis in adults and children when prescribed by a qualified health professional.

GNH USA supplies Nicozid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isoniazid is an antitubercular drug that targets Mycobacterium tuberculosis infection and related preventive strategies.

- Tuberculosis (active disease): forms part of combination therapy to eradicate Mycobacterium tuberculosis. - Latent TB infection: used to prevent progression to active disease in individuals with a positive tuberculin test. - Post‑exposure prophylaxis: administered to recent contacts of confirmed TB cases to reduce infection risk.

Isoniazid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Loss of appetite: reduced desire to eat. - Peripheral neuropathy: tingling or numbness, especially in the extremities. - Rash or mild skin eruption. - Fever or flu‑like symptoms. - Elevated liver enzymes without clinical symptoms.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury, jaundice, or hepatitis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Severe allergic reactions: anaphylaxis, angioedema. - Blood dyscrasias: agranulocytosis, thrombocytopenia. - Seizures: particularly in overdose or with pre‑existing CNS disease. - Peripheral neuropathy requiring medical intervention.

Use of Nicozid requires careful monitoring and patient education.

- Liver function monitoring: obtain baseline and periodic liver enzyme tests. - Neuropathy prevention: co‑administer pyridoxine (vitamin B6) to reduce peripheral nerve damage. - Alcohol consumption: advise avoidance or limitation to lower hepatotoxic risk. - Pregnancy assessment: evaluate risk‑benefit ratio before prescribing. - Drug interaction review: check for concomitant hepatotoxic or enzyme‑inducing agents. - Store at ambient temperature: keep in original container, protect from moisture and light.

Isoniazid can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Rifampicin: combined use increases risk of liver injury. - Phenytoin: may reduce isoniazid plasma concentrations. - Alcohol: synergistic hepatotoxic effect.

Moderate Interactions (Monitor Closely): - Acetylator status: fast acetylators clear the drug more quickly, affecting effectiveness. - Carbamazepine: additive hepatotoxic potential, requires liver function monitoring. - Sulfonamides: may increase hypersensitivity reactions when used together.